These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 39162260)
1. An automated positive selection screen in yeast provides support for boron-containing compounds as inhibitors of SARS-CoV-2 main protease. Sigurdardóttir S; Silva SF; Tiukova I; Alalam H; King RD; Grøtli M; Eriksson LA; Sunnerhagen P Microbiol Spectr; 2024 Oct; 12(10):e0124924. PubMed ID: 39162260 [TBL] [Abstract][Full Text] [Related]
2. Conserved interactions required for inhibition of the main protease of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Shitrit A; Zaidman D; Kalid O; Bloch I; Doron D; Yarnizky T; Buch I; Segev I; Ben-Zeev E; Segev E; Kobiler O Sci Rep; 2020 Nov; 10(1):20808. PubMed ID: 33257760 [TBL] [Abstract][Full Text] [Related]
3. Discovery of potential inhibitors targeting SARS-CoV-2 Mpro. Zhou WW; Li DS; Chen Y; You BQ; Zheng YF; Li Y; Si SY; Zhang J Eur Rev Med Pharmacol Sci; 2024 Sep; 28(18):4313-4325. PubMed ID: 39359203 [TBL] [Abstract][Full Text] [Related]
5. Development of a sensitive high-throughput enzymatic assay capable of measuring sub-nanomolar inhibitors of SARS-CoV2 Mpro. Kovar P; Richardson PL; Korepanova A; Afanador GA; Stojkovic V; Li T; Schrimpf MR; Ng TI; Degoey DA; Gopalakrishnan SM; Chen J SLAS Discov; 2024 Sep; 29(6):100179. PubMed ID: 39151824 [TBL] [Abstract][Full Text] [Related]
6. Inhibitors of SARS-CoV-2 Main Protease (Mpro) as Anti-Coronavirus Agents. Zagórska A; Czopek A; Fryc M; Jończyk J Biomolecules; 2024 Jul; 14(7):. PubMed ID: 39062511 [TBL] [Abstract][Full Text] [Related]
7. Structure-based screening of novel lichen compounds against SARS Coronavirus main protease (Mpro) as potentials inhibitors of COVID-19. Joshi T; Sharma P; Joshi T; Pundir H; Mathpal S; Chandra S Mol Divers; 2021 Aug; 25(3):1665-1677. PubMed ID: 32602074 [TBL] [Abstract][Full Text] [Related]
8. Ensemble docking based virtual screening of SARS-CoV-2 main protease inhibitors. Fomina AD; Uvarova VI; Kozlovskaya LI; Palyulin VA; Osolodkin DI; Ishmukhametov AA Mol Inform; 2024 Aug; 43(8):e202300279. PubMed ID: 38973780 [TBL] [Abstract][Full Text] [Related]
9. Covalent small-molecule inhibitors of SARS-CoV-2 Mpro: Insights into their design, classification, biological activity, and binding interactions. Shawky AM; Almalki FA; Alzahrani HA; Abdalla AN; Youssif BGM; Ibrahim NA; Gamal M; El-Sherief HAM; Abdel-Fattah MM; Hefny AA; Abdelazeem AH; Gouda AM Eur J Med Chem; 2024 Nov; 277():116704. PubMed ID: 39121741 [TBL] [Abstract][Full Text] [Related]
10. Using Chou's 5-steps rule to study pharmacophore-based virtual screening of SARS-CoV-2 Mpro inhibitors. Pundir H; Joshi T; Joshi T; Sharma P; Mathpal S; Chandra S; Tamta S Mol Divers; 2021 Aug; 25(3):1731-1744. PubMed ID: 33079314 [TBL] [Abstract][Full Text] [Related]
11. In silico screening of potential inhibitors from Cordyceps species against SARS-CoV-2 main protease. Deshmukh N; Talkal R; Lakshmi B J Biomol Struct Dyn; 2024 Jun; 42(9):4395-4411. PubMed ID: 37325819 [TBL] [Abstract][Full Text] [Related]
13. Development of a Biosafety Level 1 Cellular Assay for Identifying Small-Molecule Antivirals Targeting the Main Protease of SARS-CoV-2: Evaluation of Cellular Activity of GC376, Boceprevir, Carmofur, Ebselen, and Selenoneine. Fukumoto Y; Suzuki N; Hara R; Tanaka YK; Ogra Y Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891954 [TBL] [Abstract][Full Text] [Related]
14. Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of Nsp5 main protease. Milligan JC; Zeisner TU; Papageorgiou G; Joshi D; Soudy C; Ulferts R; Wu M; Lim CT; Tan KW; Weissmann F; Canal B; Fujisawa R; Deegan T; Nagaraj H; Bineva-Todd G; Basier C; Curran JF; Howell M; Beale R; Labib K; O'Reilly N; Diffley JFX Biochem J; 2021 Jul; 478(13):2499-2515. PubMed ID: 34198327 [TBL] [Abstract][Full Text] [Related]
15. Isatin-based virtual high throughput screening, molecular docking, DFT, QM/MM, MD and MM-PBSA study of novel inhibitors of SARS-CoV-2 main protease. Varadharajan V; Arumugam GS; Shanmugam S J Biomol Struct Dyn; 2022 Oct; 40(17):7852-7867. PubMed ID: 33764269 [TBL] [Abstract][Full Text] [Related]
16. Identification of potential plant-based inhibitor against viral proteases of SARS-CoV-2 through molecular docking, MM-PBSA binding energy calculations and molecular dynamics simulation. Gogoi B; Chowdhury P; Goswami N; Gogoi N; Naiya T; Chetia P; Mahanta S; Chetia D; Tanti B; Borah P; Handique PJ Mol Divers; 2021 Aug; 25(3):1963-1977. PubMed ID: 33856591 [TBL] [Abstract][Full Text] [Related]
18. Glycyrrhizic acid conjugates with amino acid methyl esters target the main protease, exhibiting antiviral activity against wild-type and nirmatrelvir-resistant SARS-CoV-2 variants. Le UNP; Chang YJ; Lu CH; Chen Y; Su WC; Chao ST; Baltina LA; Petrova SF; Li SR; Hung MC; Lai MMC; Baltina LA; Lin CW Antiviral Res; 2024 Jul; 227():105920. PubMed ID: 38821317 [TBL] [Abstract][Full Text] [Related]
19. Depicting the inhibitory potential of polyphenols from Ghosh R; Chakraborty A; Biswas A; Chowdhuri S J Biomol Struct Dyn; 2022 Jun; 40(9):4110-4121. PubMed ID: 33292085 [TBL] [Abstract][Full Text] [Related]
20. An Updated Review on SARS-CoV-2 Main Proteinase (M Sabbah DA; Hajjo R; Bardaweel SK; Zhong HA Curr Top Med Chem; 2021; 21(6):442-460. PubMed ID: 33292134 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]